Edward Lloyd Briercheck, J Michael Wrigglesworth, Ines Garcia-Gonzalez, Catherina Scheepers, Mei Ching Ong, Viji Venkatesh, Philip Stevenson, Alicia A Annamalay, David G Coffey, Aparna B Anderson, Pat Garcia-Gonzalez, Michael J Wagner
IMPORTANCE: Gastrointestinal stromal tumor (GIST) is a rare cancer treated with the tyrosine kinase inhibitors imatinib mesylate or sunitinib malate. In general, in low- and middle-income countries (LMICs), access to these treatments is limited. OBJECTIVE: To describe the demographic characteristics, treatment duration, and survival of patients with GIST in LMICs treated with imatinib and sunitinib through The Max Foundation programs. DESIGN, SETTING, AND PARTICIPANTS: This retrospective database cohort analysis included patients in 2 access programs administered by The Max Foundation: the Glivec International Patient Assistance Program (GIPAP), from January 1, 2001, to December 31, 2016, and the Max Access Solutions (MAS) program, January 1, 2017, to October 12, 2020...
April 1, 2024: JAMA Network Open